SOLTI-2201 ACROSS-TROP2 trial: A phase II study to identify predictive biomarkers of sacituzumab govitecan benefit and to understand resistance mechanisms in HR+/HER2- advanced or metastatic breast cancer.

Authors: Eva Maria Ciruelos, Tomás Pascual, Isabel Blancas, Maria Borrell, Rafael Villanueva-Vázquez, Barbara Adamo, Manuel Alva Bianchi, Lidia Carnerero Córdoba, Mireia Melé Olivé, Juan Miguel Cejalvo, Javier Salvador Bofill, Angelica Ferrando-Diez, Yann Izarzugaza Peron, Aranzazu Fernández, Xavier Gonzalez, Guillermo Villacampa, Mariana Paes Dias, Juan Manuel Ferrero-Cafiero, Mafalda Oliveira

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps1123

Source: Full article

---

Abstract

TPS1123